Phenotype
|
Fish
|
Conditions
|
Figures
|
intermediate cell mass of mesoderm drll.3 expression increased amount, abnormal
|
AB + MO1-spi1b
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
intermediate cell mass of mesoderm drll.1 expression increased amount, abnormal
|
AB + MO1-spi1b
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
macrophage absent, abnormal
|
AB + MO1-spi1b
|
standard conditions
|
Fig. 9
from Mathew et al., 2007
|
neutrophil absent, abnormal
|
AB + MO1-spi1b
|
standard conditions
|
Fig. 9
from Mathew et al., 2007
Fig. 4
from Mathias et al., 2007
|
phagocytosis decreased occurrence, abnormal
|
AB + MO1-spi1b
|
standard conditions
|
Fig. 1
from van der Vaart et al., 2013
|
monocyte lcp1 expression decreased amount, abnormal
|
AB + MO1-spi1b
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
intermediate cell mass of mesoderm drl expression increased amount, abnormal
|
AB + MO1-spi1b
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
intermediate cell mass of mesoderm drll.2 expression increased amount, abnormal
|
AB + MO1-spi1b
|
standard conditions
|
Fig. 6
from Pimtong et al., 2014
|
midbrain myeloid cell decreased amount, abnormal
|
WT + MO1-spi1b
|
amputation: caudal fin
|
Fig. 3
from Chen et al., 2022
|
myeloid cell absent, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 1,
Fig. 3
from Zakrzewska et al., 2010
|
common cardinal vein blood vessel endothelial cell increased amount, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 8
from Helker et al., 2013
|
whole organism dead, abnormal
|
WT + MO1-spi1b
|
fungal treatment: Aspergillus fumigatus
|
Fig. 1
from Knox et al., 2014
|
brain apoptotic cell clearance decreased occurrence, abnormal
|
WT + MO1-spi1b
|
control
|
Fig. 2
from Mazaheri et al., 2014
|
defense response to fungus process quality, abnormal
|
WT + MO1-spi1b
|
fungal treatment: Aspergillus fumigatus
|
Fig. 1
from Knox et al., 2014
|
regulation of myeloid leukocyte differentiation disrupted, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 3,
Fig. 4,
Fig. 5
from Bukrinsky et al., 2009
|
whole organism decreased life span, abnormal
|
WT + MO1-spi1b
|
fungal treatment: Aspergillus fumigatus
|
Fig. 1
from Knox et al., 2014
|
macrophage decreased amount, abnormal
|
WT + MO1-spi1b
|
amputation: caudal fin
|
Fig. 4
from Hasegawa et al., 2017
|
regenerating fin decreased length, abnormal
|
WT + MO1-spi1b
|
physical alteration: anatomical structure, chemical treatment: dibenziodolium
|
Fig. 2
from Yoo et al., 2012
|
regenerating fin decreased length, abnormal
|
WT + MO1-spi1b
|
physical alteration: anatomical structure, chemical treatment: EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
|
Fig. 2
from Yoo et al., 2012
|
regenerating fin apoptotic process increased occurrence, abnormal
|
WT + MO1-spi1b
|
amputation: caudal fin
|
Fig. 4 ,
Fig. 5
from Hasegawa et al., 2017
|
muscle degenerate, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 8
from Walters et al., 2009
|
neutrophil decreased amount, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 8
from Walters et al., 2009
|
caudal fin regenerating fin il1b expression increased amount, abnormal
|
WT + MO1-spi1b
|
amputation: caudal fin
|
Fig. 5
from Hasegawa et al., 2017
|
macrophage decreased amount, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 8
from Helker et al., 2013
|
blood island lacks parts or has fewer parts of type macrophage, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 3,
Fig. 5
from Bukrinsky et al., 2009
|
brain lacks all parts of type microglial cell, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 1
from Villani et al., 2019
Fig. 3
from Rossi et al., 2015
Fig. S7
from Flinn et al., 2013
|
optic tectum microglial cell absent, abnormal
|
WT + MO1-spi1b
|
control
|
Figure 2
from Hassan-Abdi et al., 2019
|
neutrophil decreased amount, abnormal
|
WT + MO1-spi1b
|
amputation: caudal fin
|
Fig. 4
from Hasegawa et al., 2017
|
yolk lacks parts or has fewer parts of type granulocyte, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 3,
Fig. 5
from Bukrinsky et al., 2009
|
optic tectum microglial cell ab2-lcp1 labeling absent, abnormal
|
WT + MO1-spi1b
|
control
|
Figure 2
from Hassan-Abdi et al., 2019
|
whole organism il1b expression decreased amount, abnormal
|
WT + MO1-spi1b
|
control
|
Figure 2
from Hassan-Abdi et al., 2019
|
posterior lateral line ganglion apoptotic process increased occurrence, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 4
from Mikdache et al., 2019
|
whole organism decreased life span, abnormal
|
WT + MO1-spi1b
|
viral treatment: Sprivivirus cyprinus
|
Fig. 6
from Varela et al., 2014
|
blood island macrophage decreased amount, abnormal
|
WT + MO1-spi1b
|
control
|
Fig. 1
from Tenor et al., 2015
|
posterior lateral line ganglion has fewer parts of type neuron, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 4
from Mikdache et al., 2019
|
brain phagocytosis decreased occurrence, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 1
from Villani et al., 2019
|
yolk lacks parts or has fewer parts of type macrophage, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 3,
Fig. 5
from Bukrinsky et al., 2009
|
whole organism cxcl8a expression decreased amount, abnormal
|
WT + MO1-spi1b
|
control
|
Figure 2
from Hassan-Abdi et al., 2019
|
microglia development arrested, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. S7
from Flinn et al., 2013
|
blood island lacks parts or has fewer parts of type granulocyte, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 3,
Fig. 5
from Bukrinsky et al., 2009
|
microglia development decreased occurrence, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 3
from Rossi et al., 2015
|
regenerating fin apoptotic process occurrence, ameliorated
|
WT + MO1-spi1b
|
chemical treatment by environment: dexamethasone, amputation: caudal fin
|
Fig. 5
from Hasegawa et al., 2017
|
neuron axon decreased amount, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 4
from Mikdache et al., 2019
|
whole organism decreased life span, abnormal
|
WT + MO1-spi1b
|
fungal treatment by injection
|
Fig. 1
from Tenor et al., 2015
|
midbrain myeloid cell decreased amount, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 3
from Chen et al., 2022
|
whole organism decreased life span, abnormal
|
WT + MO1-spi1b
|
viral treatment: Chikungunya virus
|
Fig. 7
from Palha et al., 2013
|
response to virus process quality, abnormal
|
WT + MO1-spi1b
|
viral treatment: Chikungunya virus
|
Fig. 7
from Palha et al., 2013
|
microglial cell absent, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 2
from Mazaheri et al., 2014
Fig. 4
from Peri et al., 2008
|
whole organism tnfa expression decreased amount, abnormal
|
WT + MO1-spi1b
|
standard conditions
|
Fig. 7
from Espín-Palazón et al., 2014
|
head macrophage mCherry expression decreased distribution, abnormal
|
gl23Tg + MO1-spi1b
|
standard conditions
|
Fig. 4
from Chernyavskaya et al., 2017
|
granuloma formation increased occurrence, abnormal
|
i114Tg + MO1-spi1b
|
bacterial treatment by injection: Mycobacterium marinum E11
|
Fig. 2
from Carvalho et al., 2011
|
macrophage activation involved in immune response disrupted, abnormal
|
i114Tg + MO1-spi1b
|
bacterial treatment by injection: Mycobacterium marinum E11
|
Fig. 2
from Carvalho et al., 2011
|
head neutrophil DsRed2 expression decreased distribution, abnormal
|
nz50Tg + MO1-spi1b
|
standard conditions
|
Fig. 4
from Chernyavskaya et al., 2017
|
blood island neutrophil decreased amount, abnormal
|
nz117Tg + MO1-spi1b
|
control
|
Fig. 1
from Tenor et al., 2015
|
neutrophil absent, abnormal
|
uwm4Tg + MO1-spi1b
|
standard conditions
|
Fig. 2
from Yoo et al., 2012
|
brain myeloid cell EGFP expression decreased amount, abnormal
|
zdf11Tg + MO1-spi1b
|
standard conditions
|
Fig. 3
from Chen et al., 2022
|
midbrain myeloid cell decreased amount, ameliorated
|
zdf11Tg + MO1-spi1b
|
amputation: caudal fin
|
Fig. 3
from Chen et al., 2022
|
midbrain myeloid cell decreased amount, abnormal
|
zdf11Tg + MO1-spi1b
|
standard conditions
|
Fig. 3
from Chen et al., 2022
|
midbrain blood vasculature has fewer parts of type macrophage, abnormal
|
la4Tg; zf149Tg + MO1-spi1b
|
standard conditions
|
Fig. 7
from Chen et al., 2012
|
macrophage decreased amount, abnormal
|
hey2m145/m145 + MO1-spi1b
|
standard conditions
|
Fig. 5
from Gray et al., 2007
|
dorsal aorta closed, abnormal
|
hey2m145/m145 + MO1-spi1b
|
standard conditions
|
Fig. 5
from Gray et al., 2007
|
blood circulation disrupted, abnormal
|
hey2m145/m145 + MO1-spi1b
|
standard conditions
|
Fig. 5
from Gray et al., 2007
|
muscle degenerate, abnormal
|
noc3lhi1019Tg/hi1019Tg + MO1-spi1b
|
standard conditions
|
Fig. 8
from Walters et al., 2009
|
neutrophil decreased amount, abnormal
|
noc3lhi1019Tg/hi1019Tg + MO1-spi1b
|
standard conditions
|
Fig. 8
from Walters et al., 2009
|
dopaminergic neuron decreased amount, abnormal
|
pink1sh397/sh397 + MO1-spi1b
|
standard conditions
|
text only
from Flinn et al., 2013
|
dopaminergic neuron differentiation process quality, abnormal
|
pink1sh397/sh397 + MO1-spi1b
|
standard conditions
|
text only
from Flinn et al., 2013
|
brain lacks all parts of type microglial cell, abnormal
|
slc37a2t30301/t30301 + MO1-spi1b
|
standard conditions
|
Fig. 1
from Villani et al., 2019
|
brain phagocytosis decreased occurrence, abnormal
|
slc37a2t30301/t30301 + MO1-spi1b
|
standard conditions
|
Fig. 1
from Villani et al., 2019
|
leukocyte absent, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b
|
standard conditions
|
Fig. 6
from Carney et al., 2007
|
epidermis development disrupted, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b
|
standard conditions
|
Fig. 6
from Carney et al., 2007
|
epidermis development disrupted, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b (AB)
|
standard conditions
|
Fig. 4
from Mathias et al., 2007
|
epidermis disorganized, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b (AB)
|
standard conditions
|
Fig. 4
from Mathias et al., 2007
|
macrophage absent, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b (AB)
|
standard conditions
|
Fig. S1
from Mathias et al., 2007
|
median fin fold degenerate, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b (AB)
|
standard conditions
|
Fig. 4
from Mathias et al., 2007
|
neutrophil absent, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b (AB)
|
standard conditions
|
Fig. 4
from Mathias et al., 2007
|
extension degenerate, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b (AB)
|
standard conditions
|
Fig. 4
from Mathias et al., 2007
|
median fin fold morphology, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b (AB)
|
standard conditions
|
Fig. S1
from Mathias et al., 2007
|
cell population proliferation increased rate, abnormal
|
spint1ahi2217Tg/hi2217Tg + MO1-spi1b (AB)
|
standard conditions
|
Fig. 4
from Mathias et al., 2007
|
brain apoptotic process decreased occurrence, abnormal
|
WT + MO1-casp3a + MO1-spi1b
|
chemical treatment: Z-Val-Ala-Asp(OMe)-CH2F
|
Fig. 2
from Casano et al., 2016
|
regenerating fin apoptotic process occurrence, ameliorated
|
WT + MO1-il1b + MO1-spi1b
|
amputation: caudal fin
|
Fig. 5
from Hasegawa et al., 2017
|
caudal hematopoietic tissue hematopoietic multipotent progenitor cell decreased amount, abnormal
|
WT + MO1-spi1b + MO2-spi1a
|
chemical treatment by environment: nigericin
|
Fig. 5
from Frame et al., 2020
|
caudal hematopoietic tissue hematopoietic multipotent progenitor cell decreased amount, abnormal
|
WT + MO1-spi1b + MO2-spi1a
|
standard conditions
|
Fig. 5
from Frame et al., 2020
|
whole organism runx1 expression decreased amount, abnormal
|
WT + MO1-spi1b + MO2-spi1a
|
standard conditions
|
Fig. 5
from Frame et al., 2020
|
regulation of hydrogen peroxide metabolic process disrupted, abnormal
|
WT + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. 1
from Pase et al., 2012
|
head epidermis irg1l expression position, ameliorated
|
WT + MO1-spi1b + MO4-csf3r
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2014
|
neuromast epithelium irg1l expression position, ameliorated
|
WT + MO1-spi1b + MO4-csf3r
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2014
|
epithelial cell irg1l expression position, ameliorated
|
WT + MO1-spi1b + MO4-csf3r
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2014
|
olfactory epithelium irg1l expression position, ameliorated
|
WT + MO1-spi1b + MO4-csf3r
|
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium
|
Fig. 2
from Hall et al., 2014
|
axon regeneration occurrence, ameliorated
|
irf8st95/st95 + MO1-csf3r + MO1-spi1b
|
transection: spinal cord
|
Fig. 9
from Tsarouchas et al., 2018
|
whole organism tnfa expression decreased amount, abnormal
|
irf8st95/st95 + MO1-csf3r + MO1-spi1b
|
transection: spinal cord
|
Fig. 9
from Tsarouchas et al., 2018
|
regenerating tissue neutrophil increased amount, abnormal
|
irf8st95/st95 + MO1-csf3r + MO1-spi1b
|
transection: spinal cord
|
Fig. 9
from Tsarouchas et al., 2018
|
whole organism il1b expression decreased amount, abnormal
|
irf8st95/st95 + MO1-csf3r + MO1-spi1b
|
transection: spinal cord
|
Fig. 9
from Tsarouchas et al., 2018
|
locomotion process quality, ameliorated
|
irf8st95/st95 + MO1-csf3r + MO1-spi1b
|
transection: spinal cord
|
Fig. 9
from Tsarouchas et al., 2018
|
macrophage decreased amount, abnormal
|
gl23Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. S4
from Gauert et al., 2020
|
liver size, ameliorated
|
gz32Tg + MO1-spi1b
|
chemical treatment: doxycycline
|
Fig. 3
from Yan et al., 2017
|
brain apoptotic cell clearance decreased occurrence, abnormal
|
hdb6Tg + MO1-spi1b
|
control
|
Fig. 2
from Mazaheri et al., 2014
|
microglial cell absent, abnormal
|
hdb6Tg + MO1-spi1b
|
control
|
Fig. 2
from Mazaheri et al., 2014
|
macrophage differentiation disrupted, abnormal
|
nz50Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. S4
from Feng et al., 2012
|
neutrophil decreased amount, abnormal
|
nz50Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: prostaglandin E2
|
Fig. S4
from Feng et al., 2012
|
neutrophil decreased amount, abnormal
|
nz50Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. S3 ,
Fig. S4
from Feng et al., 2012
|
neutrophil differentiation disrupted, abnormal
|
nz50Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. S4
from Feng et al., 2012
|
macrophage decreased amount, abnormal
|
nz50Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: prostaglandin E2
|
Fig. S4
from Feng et al., 2012
|
macrophage decreased amount, abnormal
|
nz50Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. S4
from Feng et al., 2012
|
neutrophil differentiation disrupted, abnormal
|
nz50Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: prostaglandin E2
|
Fig. S4
from Feng et al., 2012
|
macrophage differentiation disrupted, abnormal
|
nz50Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: prostaglandin E2
|
Fig. S4
from Feng et al., 2012
|
muscle cell cell wall repair process quality, abnormal
|
gl22Tg + MO1-irf8 + MO1-spi1b + MO3-csf3r
|
light damage: sarcolemma: muscle cell
|
Fig. 1
from Middel et al., 2016
|
macrophage absent, abnormal
|
gl22Tg + MO1-irf8 + MO1-spi1b + MO3-csf3r
|
light damage: sarcolemma: muscle cell
|
Fig. 1
from Middel et al., 2016
|
liver size, ameliorated
|
gz32Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: doxycycline
|
Fig. 3
from Yan et al., 2017
|
liver macrophage amount, ameliorated
|
gl22Tg; gz32Tg + MO1-spi1b
|
chemical treatment: doxycycline
|
Fig. 3
from Yan et al., 2017
|
defense response to fungus increased efficacy, abnormal
|
gl23Tg; i113Tg + MO1-spi1b + MO3-csf3r
|
fungal treatment by injection: Talaromyces marneffei
|
Fig. 5
from Ellett et al., 2018
|
macrophage decreased amount, abnormal
|
gl23Tg; i113Tg + MO1-spi1b + MO3-csf3r
|
control
|
Fig. 5
from Ellett et al., 2018
|
neutrophil decreased amount, abnormal
|
gl23Tg; i113Tg + MO1-spi1b + MO3-csf3r
|
control
|
Fig. 5
from Ellett et al., 2018
|
neutrophil decreased amount, abnormal
|
gl23Tg; i114Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. S4
from Gauert et al., 2020
|
macrophage decreased amount, abnormal
|
gl23Tg; i114Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. S4
from Gauert et al., 2020
|
liver neutrophil increased amount, abnormal
|
gz32Tg; nz50Tg + MO1-spi1b
|
chemical treatment: doxycycline
|
Fig. 3
from Yan et al., 2017
|
mucus secreting cell decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell proliferative, abnormal
|
hzm1Et; io006Tg + MO1-spi1b
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
macrophage decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell proliferative, abnormal
|
hzm1Et; io006Tg + MO1-spi1b
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
macrophage decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
whole organism Ab11-tau labeling increased amount, abnormal
|
mde3Tg; mde4Tg + MO1-spi1b
|
control
|
Figure 2
from Hassan-Abdi et al., 2019
|
whole organism il1b expression increased amount, abnormal
|
mde3Tg; mde4Tg + MO1-spi1b
|
control
|
Figure 2
from Hassan-Abdi et al., 2019
|
whole organism cxcl8a expression increased amount, abnormal
|
mde3Tg; mde4Tg + MO1-spi1b
|
control
|
Figure 2
from Hassan-Abdi et al., 2019
|
primary motor neuron axon TagBFP expression mislocalised, abnormal
|
mq10Tg; mq14Tg + MO1-spi1b
|
light damage: primary motor neuron
|
Fig. 7
from Svahn et al., 2018
|
primary motor neuron degenerate, abnormal
|
mq10Tg; mq14Tg + MO1-spi1b
|
light damage: primary motor neuron
|
Fig. 4 ,
Fig. 5 ,
Fig. 7
from Svahn et al., 2018
|
primary motor neuron cytoplasm EGFP expression mislocalised, abnormal
|
mq10Tg; mq14Tg + MO1-spi1b
|
light damage: primary motor neuron
|
Fig. 4 ,
Fig. 5 ,
Fig. 7
from Svahn et al., 2018
|
primary motor neuron axon EGFP expression mislocalised, abnormal
|
mq10Tg; mq14Tg + MO1-spi1b
|
light damage: primary motor neuron
|
Fig. 7
from Svahn et al., 2018
|
microglial cell absent, abnormal
|
mq10Tg; mq14Tg + MO1-spi1b
|
light damage: primary motor neuron
|
Fig. 4 ,
Fig. 5 ,
Fig. 7
from Svahn et al., 2018
|
ventral wall of dorsal aorta hematopoietic stem cell decreased amount, abnormal
|
s896Tg; zf169Tg + MO1-spi1b
|
standard conditions
|
Fig. 7
from Espín-Palazón et al., 2014
|
head macrophage mCherry expression decreased distribution, abnormal
|
uhrf1hi272Tg/hi272Tg; gl23Tg + MO1-spi1b
|
standard conditions
|
Fig. 4
from Chernyavskaya et al., 2017
|
head neutrophil DsRed2 expression decreased distribution, abnormal
|
uhrf1hi272Tg/hi272Tg; nz50Tg + MO1-spi1b
|
standard conditions
|
Fig. 4
from Chernyavskaya et al., 2017
|
liver macrophage amount, ameliorated
|
gl22Tg; gz32Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: doxycycline
|
Fig. 3
from Yan et al., 2017
|
liver neutrophil amount, ameliorated
|
gz32Tg; nz50Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: doxycycline
|
Fig. 3
from Yan et al., 2017
|
notochord epithelium accumulation neutrophil, ameliorated
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. 4.
from López-Cuevas et al., 2021
|
neutrophil decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
notochord epithelium accumulation macrophage, ameliorated
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. 4.
from López-Cuevas et al., 2021
|
macrophage decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
macrophage decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell proliferative, abnormal
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell proliferative, abnormal
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. 3
from Feng et al., 2012
|
neutrophil decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
mucus secreting cell decreased amount, abnormal
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
chemical treatment: prostaglandin E2
|
Fig. 3
from Feng et al., 2012
|
notochord cell population proliferation occurrence, ameliorated
|
hzm1Et; io006Tg + MO1-spi1b + MO3-csf3r
|
standard conditions
|
Fig. 4.
from López-Cuevas et al., 2021
|
macrophage absent, abnormal
|
hzm1Et; io006Tg; nz50Tg + MO1-spi1b + MO3-csf3r
|
control
|
Fig. 3
from Antonio et al., 2015
|
neutrophil absent, abnormal
|
hzm1Et; io006Tg; nz50Tg + MO1-spi1b + MO3-csf3r
|
resection: caudal fin
|
Fig. 3
from Antonio et al., 2015
|
macrophage absent, abnormal
|
hzm1Et; io006Tg; nz50Tg + MO1-spi1b + MO3-csf3r
|
resection: caudal fin
|
Fig. 3
from Antonio et al., 2015
|
neutrophil absent, abnormal
|
hzm1Et; io006Tg; nz50Tg + MO1-spi1b + MO3-csf3r
|
control
|
Fig. 3
from Antonio et al., 2015
|
caudal fin canonical NF-kappaB signal transduction process quality, ameliorated
|
mir223pu18/pu18; nc1Tg + MO1-rac2 + MO1-spi1b
|
transection: caudal fin
|
Fig. 4
from Zhou et al., 2018
|
caudal fin EGFP expression amount, ameliorated
|
mir223pu18/pu18; nc1Tg + MO1-rac2 + MO1-spi1b
|
transection: caudal fin
|
Fig. 4
from Zhou et al., 2018
|